TICEBA STEM CELL EXPERTS
LIVE

Serial Number

79311207

Owner

Dr. Christoph Ganss

Attorney

Sean K. Owens

Filing Date

Dec 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TICEBA STEM CELL EXPERTS Trademark

Serial Number: 79311207 • Registration: 6861489

TICEBA STEM CELL EXPERTS is a trademark filed by Dr. Christoph Ganss on December 22, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Dr. Christoph Ganss (4 trademarks)

Im Bäckerfeld 2
69120 Heidelberg , DE

Entity Type: 01

Trademark Details

Filing Date

December 22, 2020

Registration Date

October 4, 2022

Published for Opposition

July 19, 2022

Goods & Services

pharmaceutical drugs, namely pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; pharmaceutical drugs for treatment of cancer, hormone replacement therapy preparations; pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing, pharmaceutical and veterinary preparations for treating diabetes, antidepressants; pharmaceutical preparations for anti-aging, pharmaceutical preparations namely antibiotics, vaccines; diagnostic agents for medical use; preparations for medical purposes, namely, for the treatment of skin diseases, allergy medication, herbal extracts for medical use, reagents for medical use; substances for medical use, namely, for regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; somatic stem cell therapeutics, namely, for medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; pharmaceutical implants, namely, implantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseases, blood diseases, vertigo, nausea, vomiting, migraine, respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system; surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; biological tissue for implantation, namely, implants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, surgical implants comprised of living tissues; biotechnologically engineered tissue products, namely, living tissue cell sheets and plasters for wound healing and burns, biological eye lens grafts, bone grafts in the nature of biological bone tissue for grafting, biological tissue grafts, human allograft tissue

Stem cells for scientific or research use; cell growth media for growing cells for scientific use

Medical services relating to the removal, treatment, processing and preservation of human blood, cord blood, human cells and tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells

Stem cell research; scientific research and development and medical research and development in the field of stem cells, vaccines and medications; scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, genetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific research, namely, technical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processes, namely, engineering of industrial processes in the field of for packaging, storage and transport of human tissue and human adult ancestral cells, engineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineering, chemical engineering

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 20, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 26, 2023 FICS
FINAL DISPOSITION PROCESSED
Jan 26, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 4, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 4, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 4, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Jul 25, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 19, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 19, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 29, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 29, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 29, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 15, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 9, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 8, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 22, 2021 GNFN
FINAL REFUSAL E-MAILED
Dec 22, 2021 GNFR
FINAL REFUSAL WRITTEN
Dec 22, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2021 TROA
REFUSAL PROCESSED BY IB
Jul 19, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 28, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jun 28, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 18, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jun 17, 2021 CNRT
ASSIGNED TO EXAMINER
Jun 16, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
May 25, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 20, 2021 REPR